← Company directoryNASDAQ · SEC EDGAR
Crinetics Pharmaceuticals, Inc.
CRNXA primary-source company identity page built for fast discovery, filing verification and consistent financial research.
SHARE PRICE · INDICATIVE——
A recent price could not be verified. Check the exchange before trading.
ANALYSIS ROUTE
Four checks before any decision
Business model
Understand how the company earns and where demand originates.
Revenue and margin
Compare equivalent periods; separate growth from profitability.
Debt and cash flow
Test balance-sheet resilience and cash conversion.
Valuation and risk
Use sector peers, scenarios and explicit risk limits.
Company calendar
CRNX suspension following the Crinetics–Vertex merger
The Vertex merger closed before the market opened on 1 September. CRNX shares remained halted on 1 September and will be suspended from Nasdaq effective 2 September. The merger consideration is $85 in cash per share.
Nasdaq ↗More NASDAQ records
Alphabetically adjacent directory records for faster navigation; this is not a peer or valuation classification.
CRMLWCritical Metals Corp. - WarrantsNASDAQ · SEC→CRMTAmerica's Car-Mart, Inc.NASDAQ · SEC→CRNCCerence Inc.NASDAQ · SEC→CRNTCeragon Networks Ltd.NASDAQ · SEC→CRONCronos Group Inc. - Common ShareNASDAQ · SEC→CROXCrocs, Inc.NASDAQ · SEC→CRSPCRISPR Therapeutics AG - Common SharesNASDAQ · SEC→CRSRCorsair Gaming, Inc.NASDAQ · SEC→
DATA STATUS
Open official filings ↗Checking SEC financial statements
A dash means standardized data is unavailable. Always check the filing period, currency and accounting scope.